Cytopathological changes in early stages of benign prostatic hyperplasia upon exposure to sustained delivery of androgens.
The objective of this study was to assess the possible morphological changes that occur in the columnar epithelial cells of the prostate peripheral zone during early development of benign prostatic hyperplasia. In this study benign prostatic hyperplasia (BPH) was encouraged by the continuous delivery of androgens using TCPL drug delivery devices. A total of 16 adult male rats were randomly divided into four groups (n = 4). Group 1 served as an intact control and Groups 2-4 were implanted with tricalcium phosphate lysine (TCPL) capsules designed to deliver continuous physiologic (40 mg) doses of specific androgens as follows: Group 2, testosterone (Test); Group 3, dihydrotestosterone (DHT); Group 4, androstenedione (AED), respectively. Upon completion of the study, the columnar epithelial cells were targeted for morphometric analysis. The means number of cells per high power field, cell length, cell area, nuclear area and nuclear to cytoplasmic ratio were measured using image analysis techniques. The results of this study showed that (1) the number of cells per high power field were not changed with treatment, (2) the cell length was decreased with treatment of all androgens, (3) the cell area was decreased with treatment, (4) the nuclear area was increased with treatment of Test and DHT, and (5) the N/C ratio was increased with all three androgens. These results suggest that very early in the development of BPH, remarkable changes occur in the nucleus of the columnar epithelial cells. These changes may indicate a specific physiological response to irritation arising from the continuous delivery of androgens.
Pollan
Melanie Callender
MC
University of Mississippi Medical Center, School of Health Related Professions, Jackson, MS 39216, USA.
Benghuzzi
Hamed A
HA
Tucci
Michelle
M
D000728:Androgens / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D015114:Androstenediol / Q000378:metabolism; D000818:Animals; D013196:Dihydrotestosterone / Q000378:metabolism; D018450:Disease Progression; D008297:Male; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000378:metabolism
D000728:Androgens; D013196:Dihydrotestosterone; D013739:Testosterone; D015114:Androstenediol